Zacks Research Predicts Sanofi’s Q3 Earnings (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) – Stock analysts at Zacks Research increased their Q3 2025 earnings per share (EPS) estimates for shares of Sanofi in a report issued on Wednesday, January 22nd. Zacks Research analyst K. Shah now forecasts that the company will post earnings per share of $1.59 for the quarter, up from their prior forecast of $1.58. The consensus estimate for Sanofi’s current full-year earnings is $3.82 per share. Zacks Research also issued estimates for Sanofi’s Q1 2026 earnings at $1.06 EPS, Q2 2026 earnings at $1.05 EPS, Q4 2026 earnings at $1.20 EPS and FY2026 earnings at $4.78 EPS.

Sanofi (NASDAQ:SNY) last posted its earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. The business had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same quarter last year, the company earned $2.55 EPS.

Separately, StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th.

Sanofi Stock Up 1.0 %

Sanofi stock opened at $52.48 on Friday. The firm has a market cap of $133.19 billion, a price-to-earnings ratio of 26.78, a PEG ratio of 1.19 and a beta of 0.57. The stock has a fifty day simple moving average of $48.70 and a two-hundred day simple moving average of $52.19. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17.

Hedge Funds Weigh In On Sanofi

A number of institutional investors and hedge funds have recently modified their holdings of SNY. Jennison Associates LLC increased its position in Sanofi by 938.0% in the third quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock worth $109,753,000 after buying an additional 1,720,972 shares in the last quarter. Thrivent Financial for Lutherans raised its stake in Sanofi by 28,890.2% during the 3rd quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock worth $82,366,000 after acquiring an additional 1,424,289 shares during the period. DAVENPORT & Co LLC lifted its holdings in Sanofi by 40.7% during the fourth quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock valued at $110,715,000 after purchasing an additional 664,455 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Sanofi by 20.9% in the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock worth $133,172,000 after purchasing an additional 399,301 shares during the period. Finally, Franklin Resources Inc. lifted its stake in shares of Sanofi by 13.1% during the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock valued at $208,106,000 after buying an additional 395,744 shares in the last quarter. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.